FEATURED EDITORIAL
Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease.
- Araris Doubles Down With Dual-payload ADC
- AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery
- Does Targeting Macrophages Hold The Key For Treating Cancer?
- Great siRNA Science Or Savvy Business Acumen? You Need Both
- The Search For A Chemotherapy-Free Treatment For Patients With Blood Cancer
- Bridge RNAs: Principles, Applications, And Challenges
- Is Your Lab Ready For A LIMS Implementation?
FEATURED APPLICATION CONTENT
-
Issues related to cleaning and cleaning validation are some of the most common concerns that arise in FDA Warning Letters. Discover how to ensure you pass your cleaning validation tests.
-
Discover the innovative methods behind CAR-T cell production, from custom plasmid design to lentiviral vector transduction, and explore their potential in revolutionizing cancer treatment.
-
Explore the results of a study focusing on the early stages of the CAR T cell workflow, specifically the initial washing of leukapheresis followed by the isolation of T cells.
-
Discover how you can achieve a final mAb concentration above 200 g/L while maintaining critical quality attributes.
-
Learn about a rapid, high-throughput method for determining the E/F ratio in the AAV drug product that is well-suited for screening both crude and purified AAV samples.
-
Gain insight into how a high-throughput capsid assay for rapid AV quantification was developed using an innovative Bio-Layer Interferometry (BLI) platform that offers high precision and reliability.
-
Examine the performance of a biosensor for AAV capsid titer measurement that offers high-precision, broad AAV serotype binding specificity, and more.
-
To address concerns about using organic solvents in the ADC process, extractables studies were conducted on a disposable chromatography column housing and two different disposable flow paths.
-
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
A healthcare manufacturer facing space constraints and regulatory pressures outsourced their stability storage needs to another company, resulting in reduced costs and focus on core competencies.
-
When facing a malfunction, having an effective disaster recovery plan can make the difference between a swift fix, and losing your samples and time.
-
A pharmaceutical company facing storage space issues decided to outsource their reference samples to Q1 Scientific, a stability storage service provider, resulting in cost savings.
FEATURED NEWS HEADLINES
- Tonix Pharmaceuticals Announces AI Collaboration With X-Chem To Develop Broad-Spectrum Antivirals
- Simulations Plus And The University Of Southern California Secure NIH Grant To Develop New AI Drug Discovery Offerings
- ProductLife Group Acquires IntiQuan, Strengthening Global Drug Development Capabilities
- New Drugs From Toxic Birds
- AI And Quantum Mechanics Team Up To Accelerate Drug Discovery
- X-Ray Scattering Breakthrough Pinpoints New Targets For Antibiotic Drug Development
- TiumBio Announces First Patient Dosed In Phase 2 Clinical Trial Of Oral Immuno-Oncology Drug TU2218
- eMolecules And Optic Join Forces To Accelerate Drugs' Time-To-Market
- Promising 'First' In Alzheimer's Drug Development
- Quantum Researchers Come Up With A Recipe That Could Accelerate Drug Development
ARCHIVED NEWSLETTER
- 10.08.24 -- Tips For Addressing Vaccine Demand – No Matter Your Therapeutic Background
- 10.08.24 -- Great siRNA Science Or Savvy Business Acumen? You Need Both
- 10.02.24 -- Dig Into Ideas, Data, And Examples Of Bioprocessing Intensification Strategies
- 10.01.24 -- Industrializing mRNA Therapeutics
- 10.01.24 -- AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery